
==== Front
Cureus
Cureus
2168-8184
Cureus
2168-8184
Cureus Palo Alto (CA)

10.7759/cureus.66974
Internal Medicine
Dermatology
Oncology
Development of Subcutaneous Panniculitis-Like T-cell Lymphoma After Immune Checkpoint Inhibitor Treatment
Muacevic Alexander
Adler John R
Yu Tommy Y 1
Gul Zartash 2
Hunt Alicia M 3
Williams Michael J 4
Maley Alexander M 5
1 Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, USA
2 Department of Oncology, Aurora St. Luke's Medical Center, Milwaukee, USA
3 Department of Pathology and Laboratory Medicine, Aurora St. Luke's Medical Center, Milwaukee, USA
4 Department of Pharmacy, Aurora St. Luke's Medical Center, Milwaukee, USA
5 Department of Dermatology, Aurora St. Luke's Medical Center, Milwaukee, USA
Tommy Y. Yu tommy.yu0594@gmail.com
15 8 2024
8 2024
16 8 e6697415 8 2024
Copyright © 2024, Yu et al.
2024
Yu et al.
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This article is available from https://www.cureus.com/articles/269896-development-of-subcutaneous-panniculitis-like-t-cell-lymphoma-after-immune-checkpoint-inhibitor-treatment
Program death 1 (PD-1) inhibitors such as nivolumab are immune checkpoint inhibitors that have revolutionized the treatment of metastatic melanoma. Despite its success in treating melanoma, immune activation can lead to immune-related adverse effects, which are experienced by half of melanoma patients treated with PD-1 inhibitors. Despite the common frequency of immune-mediated adverse events, the development of a secondary lymphoma is exceedingly rare. We present the case of a 53-year-old woman diagnosed with stage IV metastatic melanoma, treated with nivolumab, who subsequently developed fatal subcutaneous panniculitis-like T-cell lymphoma (SPTCL).

immune checkpoint inhibitor
cutaneous t-cell lymphoma
nivolumab-related adverse events
cancer immunotherapy
melanoma treatment
==== Body
pmcIntroduction

Immune checkpoint inhibitors are targeted monoclonal antibodies which block T-cell inactivation receptors which are used by malignant cells to evade the body's immune system. Through this mechanism, program death 1 (PD-1) inhibitors result in T-cell activation and proliferation. Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare primary cutaneous lymphoma derived from cytotoxic alpha-beta T cells. Most cases of SPTCL are indolent with a good prognosis. However, if complicated by hemophagocytic lymphohistiocytosis (HLH), the prognosis is poor. Nivolumab is a PD-1 inhibitor that has become the standard of care in the treatment of metastatic melanoma. Here, we present a rare case of a 53-year-old woman with stage IV metastatic melanoma, treated with nivolumab, who later developed SPTCL.

Case presentation

A 53-year-old woman presented with stage IV metastatic melanoma of the mid-upper back. She was treated with four cycles of nivolumab and ipilimumab followed by 12 cycles of nivolumab alone. She had a complete response based on PET-CT imaging. 

Two months after her last nivolumab infusion, she developed numerous indurated subcutaneous nodules on the trunk and bilateral upper extremities along with systemic complaints of fatigue, fevers, night sweats, and rigors. Excisional biopsies were performed from the abdomen and shoulder. The histopathological exam showed a lymphocytic infiltrate predominately present around the subcutaneous adipocytes and rimming the adipocyte membrane (Figure 1). Immunohistochemical staining was positive for CD3, CD8, granzyme B, and the alpha-beta T-cell receptor. Immunohistochemistry was negative for CD56, CD30, and Epstein-Barr virus (EBV).

Figure 1 Hematoxylin and eosin stain at 10× (A) and 40× (B) showing subcutaneous infiltrate of atypical lymphocytes rimming the adipocytes, which are positive for CD8 (C) and granzyme B (D), consistent with subcutaneous panniculitis-like T-cell lymphoma.

The patient was diagnosed with SPTCL. Treatment was begun with combination chemotherapy of cyclophosphamide, doxorubicin, etoposide, vincristine, and prednisone. She received four cycles of chemotherapy. Three months after her diagnosis of SPTCL, her disease was complicated by HLH with rapid progression. She was febrile with the following relevant laboratory values: ferritin 10,897 ng/mL, C-reactive protein (CRP) 8.7 mg/dL, triglycerides 175 mg/dL, red blood cell count 6.7 g/dL, platelets 18 k/mcl, and soluble IL-2 receptor 2387 pg/mL. CT scan of the abdomen showed splenomegaly; the spleen measured 16.2 cm in craniocaudal dimension. She was admitted to the intensive care unit, where she was diagnosed with septic shock complicated by respiratory and renal failure and was placed on a ventilator. She was treated with a wide spectrum of antimicrobials, including vancomycin, cefepime, acyclovir, and fluconazole, as well as multiple vasopressors such as phenylephrine, epinephrine, norepinephrine, and vasopressin. Despite these interventions, she remained hypotensive and persistently hypoxemic. Bronchoscopy revealed a cavitary lesion and necrotic lung tissue. Culture from bronchoalveolar lavage cytology grew Rhizopus microsporus. She subsequently passed away after a three-day admission. 

Discussion

PD-1 is a key checkpoint molecule that, upon binding with one of its ligands PD-L1 or PD-L2, exhibits inhibitory function in T cells, including the prevention of anti-tumor immunity. By blocking this function, PD-1 inhibitors such as nivolumab trigger an anti-tumor immune response that has been transformative in the treatment of multiple types of cancer.

While the use of PD-1 inhibitors is commonly associated with immune-related adverse events, the development and progression of T-cell lymphomas are exceedingly rare. A phase II study using nivolumab for the treatment of refractory peripheral T-cell lymphoma was terminated due to the hyperprogression of lymphoma in four of 12 patients [1]. In another phase II trial in patients with adult T-cell leukemia-lymphoma (ATLL), all three patients developed rapid progression of their lymphoma after a single dose of nivolumab [2]. In addition to leading to the hyperprogression of T-cell lymphoma, PD-1 inhibitors have also been reported to lead to the de novo development of T-cell lymphoma in multiple case reports [3,4].

The exact underlying mechanism of this rare and seemingly paradoxical complication is unknown. In a murine T-cell lymphoma model, anti-PD-1 antibodies induced massive lethal lymphoproliferation, suggesting that PD-1 not only acts as an immune checkpoint but also functions as a tumor suppressor for T cells [5]. In the terminated trial using nivolumab to treat ATLL, the authors analyzed clonality, somatic mutations, and gene expression in the malignant cells to confirm rapid clonal expansion after PD-1 blockade [6]. Their proposed mechanisms for the hyperprogression of ATLL after nivolumab include PD-1 blockade driving the expression of additional checkpoints that promote the suppressive activity of ATLL cells, PD-1 blockade altering the expression of ATLL-promoting growth factors, stromal PD-L1 acting as a tumor suppressor by binding to PD-1 expressed on leukemic cells in the ATLL microenvironment, and PD-1 uniquely governing immunity in patients with chronic or smoldering ATLL.   To our knowledge, this is the first case documenting the development of SPTCL following treatment with PD-1 inhibitor nivolumab. In a pooled report of four melanoma trials of anti-PD-1 monotherapy, 49% of patients experienced immune-related adverse events, but there were no cases of lymphoma [7]. SPTCL is a rare primary cutaneous lymphoma composed of alpha-beta cytotoxic T cells [8]. Histologically, the neoplastic T cells express CD8, beta F1, and other cytotoxic T-cell markers such as granzyme B, perforin, and TIA1 [8]. The neoplastic T-cell infiltrates tend to surround the rim of adipocytes and distort their membrane.   While most cases of SPTCL have a rather indolent course and good prognosis, our patient's disease was further complicated by HLH, a syndrome of macrophage dysfunction that can result in critical illness [8]. HLH was diagnosed by her combination of fever, anemia, thrombocytopenia, hypertriglyceridemia, elevated ferritin, soluble IL-2 receptor, and splenomegaly. HLH is seen in up to 20% of patients diagnosed with SPTCL and is associated with a poor prognosis, with a five-year survival rate of 46% compared to 91% of those without this complication [8]. There is currently no standard treatment regimen for SPTCL. Unfortunately, our patient progressed despite early treatment with chemotherapy, succumbing to shock complicated by an invasive pulmonary fungal infection.

Conclusions

Nivolumab and other PD-1 inhibitors play a central role in melanoma treatment. Progression of primary T-cell lymphomas and development of secondary T-cell lymphomas are possible immune-related adverse events following PD-1 inhibitor treatment. Physicians should be aware of this rare and potentially fatal adverse immune event. 

Disclosures

Author Contributions

Human subjects: Consent was obtained or waived by all participants in this study.

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:

Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.

Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.

Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Concept and design:  Tommy Y. Yu, Alicia M. Hunt, Alexander M. Maley, Zartash Gul

Acquisition, analysis, or interpretation of data:  Tommy Y. Yu, Alicia M. Hunt, Alexander M. Maley, Michael J. Williams, Zartash Gul

Drafting of the manuscript:  Tommy Y. Yu, Alicia M. Hunt, Alexander M. Maley, Michael J. Williams

Critical review of the manuscript for important intellectual content:  Tommy Y. Yu, Alicia M. Hunt, Alexander M. Maley, Michael J. Williams, Zartash Gul

Supervision:  Tommy Y. Yu, Alicia M. Hunt, Alexander M. Maley, Michael J. Williams, Zartash Gul
==== Refs
References

1 Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression J Immunother Cancer Bennani NN Kim HJ Pederson LD 0 10 2022
2 Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy N Engl J Med Ratner L Waldmann TA Janakiram M Brammer JE 1947 1948 378 2018 29768155
3 Nivolumab-associated cutaneous T-cell lymphoma JAAD Case Rep Marks JA Parker DC Garrot LC Lechowicz MJ 39 41 9 2021 33644277
4 Development of acute adult T-cell leukemia following PD-1 blockade therapy for lung cancer Intern Med Misawa K Yasuda H Matsuda H 3421 3424 61 2022 36385048
5 PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis Nature Wartewig T Kurgyis Z Keppler S 121 125 552 2017 29143824
6 Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade Blood Rauch DA Conlon KC Janakiram M 1406 1414 134 2019 31467059
7 Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma J Clin Oncol Weber JS Hodi FS Wolchok JD 785 792 35 2017 28068177
8 Subcutaneous panniculitis-like T-cell lymphoma StatPearls [Internet] Musick SR Lynch DT Treasure Island (FL) StatPearls Publishing 2024 https://www.ncbi.nlm.nih.gov/books/NBK538517/
